✦ LIBER ✦

785 SORAFENIB PLUS OCTREOTIDE IN ADVANCED HEPATOCELLULAR CARCINOMA: UPDATED RESULTS OF A MULTICENTER STUDY

✍ Scribed by S. Del Prete; R. Addeo; M. Caraglia; L. Maiorino; V. Montesarchio; G. Cennamo; R. Guarrasi; V. Faiola; L. Leo; A. Febbraro; B. Vincenzi; C. Savastano; L. Tarantino; A. Sabia; E. Capasso; G. Palmieri; A. Giorgio; M. Bianco; L. Montella

Book ID: 117377792
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 49 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(09)60787-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sorafenib plus long-acting octreotide in

Sorafenib plus long-acting octreotide in advanced hepatocellular carcinoma. Preliminary results of a multicenter ongoing study

✍ S. Del Prete; R. Addeo; L. Maiorino; G. Cennamo; V. Montesarchio; L. Leo; V. Fai 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 79 KB

Sorafenib plus octreotide is an effectiv

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

✍ Salvatore Del Prete; Liliana Montella; Michele Caraglia; Luigi Maiorino; Gregori 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 378 KB

79 SORAFENIB PLUS TACE FOR THE TREATMENT

79 SORAFENIB PLUS TACE FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA – FINAL RESULTS OF THE SOCRATES TRIAL

✍ A. Erhardt; F.T. Kolligs; M. Dollinger; E. Schott; H. Wege; M. Bitzer; C. Gog; J 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Field-practice study of sorafenib therap

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

✍ Massimo Iavarone; Giuseppe Cabibbo; Fabio Piscaglia; Claudio Zavaglia; Antonio G 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 2 views

on behalf of the SOFIA (SOraFenib Italian Assessment) study group A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib a

3500 ORAL Preliminary results from a pha

3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma

✍ G.K. Abou Alfa; P. Johnson; J. Knox; J. Lacava; T. Leung; A. Mori; M.A. Leberre; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 56 KB

281 Efficacy of long acting release octr

281 Efficacy of long acting release octreotide in patients with advanced hepatocellular carcinoma: A randomized multicenter phase III study

✍ C. Verslype; G. Verset; H. Reynaert; I. Borbath; P. Langlet; A. Vandebroek; M. P 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 128 KB